Catalyst Dossier · compiled by CeliA 🧫

BAYER (BAYRY)

Healthcare · market cap $42.5B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-31 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Bayer AG (BAYRY) is a diversified global healthcare and life-sciences conglomerate with 88,502 employees and a market cap of approximately $42.5B. The company carries a broad late-stage pipeline spanning cardiovascular, renal, oncology, women's health, and diagnostic imaging, with several high-importance catalysts expected through mid-2027. Key near-term binary events include Phase 3 readouts for BAY3723113 (August 2026) and Finerenone in CKD (May 2027), alongside earlier-stage data for the hemophilia asset DTX201 and the EGFR-mutant NSCLC candidate BAY2927088.

The catalyst path

2026-08-31 (est.)Phase 3 · BAY3723113imp 9/10
2026-09-15 (est.)Phase 2 · BAY2599023 (DTX201)imp 7/10
2027-02-03 (est.)Phase 3 · BAY2927088imp 9/10
2027-02-03 (est.)Phase 2 · BAY2927088imp 7/10
2027-05-31 (est.)Phase 3 · Finerenone (Kerendia, BAY94-8862)imp 9/10

Pipeline

Asset	Phase	Indication
D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV	Phase 3	Acute Coronary Syndrome
Finerenone (Kerendia, BAY94-8862)	Phase 3	Chronic Kidney Disease
Oxybutynin (Oxytrol, BAY839380)	Phase 3	Overactive Bladder
Amikacin Inhalation Solution (BAY41-6551)	Phase 3	Pneumonia, Bacterial
Darbepoetin	Phase 2	Anemia
Naproxen gel	Phase 2	Soft Tissue Injury
Amikacin (BAY41-6551)	Phase 2	Pneumonia
BAY94-8862	Phase 2	Diabetic Nephropathies
Regorafenib (Stivarga, BAY73- 4506)	Phase 3	Colorectal Neoplasms
EE20/DRSP (YAZ, BAY86-5300)	Phase 3	Oral Contraceptive
Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine	Phase 3	Common Cold
Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)	Phase 3	Drugs, Investigational
RDEA119	Phase 2	Advanced Cancer
Gadoquatrane (BAY1747846)	Phase 3	Contrast Enhancement in Magnetic Resonance Imaging
Laif® 900, BAY98-7108	Phase 3	Moderate Depressive Episodes (Major Depression)
Vilaprisan (BAY1002670)	Phase 2	Leiomyoma
omeprazole magnesium (20 mg equivalent)	Phase 3	Gastric Acid
Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)	Phase 2	Brain Diseases
Ciprofloxacin (Cipro, BAYQ3939)	Phase 3	Pneumonia
Naproxen Sodium ER (BAYH6689)	Phase 3	Pain

Price & technical context

3-month

+28.5%

6-month

+35.2%

12-month

+108.7%

52-wk range

$4.86–$10.69

vs 50-day MA

+19.2%

vs 200-day MA

+34.5%

Realized vol

49.9%

Max drawdown

-42.8%

Daily closes through 2025-12-22. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BAYRY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.